This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Glaukos (GKOS) Loses 14.3% Despite Narrower Loss in Q1
by Zacks Equity Research
Despite reporting first-quarter loss, Glaukos' (GKOS) results reflect rise in revenues.
Fresenius Medical (FMS) Gains 1.1% Since Q1 Earnings Beat
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter earnings benefit from organic growth in Health Care Products segment, and performance in Asia Pacific.
LHC Group (LHCG) Loses 1.1% In Spite of Q1 Earnings Beat
by Zacks Equity Research
LHC Group's (LHCG) first-quarter results benefit from organic growth in hospice admissions.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) continues to gain from its core Chronic Care segment in the first quarter.
Here's Why You Should Buy National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision (EYE) backed by its improvement in comparable store sales (comps) in eyeglasses and contact lens.
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare (AMN) gains from segmental strength in the first quarter.
Nevro (NVRO) Stock Slips 2.9% Despite Narrower Loss in Q1
by Zacks Equity Research
Nevro's (NVRO) international revenues rise on a year-over-year basis in Q1.
McKesson (MCK) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) witnesses revenue growth in each of its segments in the first quarter.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.
Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1
by Zacks Equity Research
Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.
Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.
PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.
Integer (ITGR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Integer (ITGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.
Integer (ITGR) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 12.79% and 2.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integer (ITGR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE
by Zacks Equity Research
Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Integer (ITGR) Up 7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integer (ITGR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Integer Holdings (ITGR) Gains 2.4% Post Q4 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect weak segmental performance.